Next, through a convenient telehealth appointment, our provider will evaluate your medical history and weight loss objectives, creating a personalized tirzepatide treatment plan
In the OASIS 4 phase 3 trial, oral semaglutide 25mg was studied in adults with overweight or obesity without type 2 diabetes
A survey of the mouse hindbrain in the fed and fasted states using single-nucleus RNA sequencing
[4] A major double-blind study (17,604 participants) showed semaglutide (Wegovy) reduces major adverse cardiovascular events by 20% in adults with overweight/obesity and established cardiovascular disease, but without diabetes
Consistency: Administer at consistent intervals each day to maintain stable B12 exposure
Risk Factors Metabolic syndrome (strongest risk factor) increased waist circumference (obesity) insulin resistance elevations in: blood sugar cholesterol triglycerides blood pressure uric acid Diabetes (up to 75% of individuals with type 2 diabetes have NAFLD) Sleep apnea Gut microbiome effects Genetic factors Why is it important to address
